Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference121 articles.
1. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives;Majidpoor;Clin. Immunol.,2021
2. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies;Denkert;The Lancet,2017
3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021
4. The current knowledge concerning solid cancer and therapy;Najafi;J. Biochem. Mol. Toxicol.,2021
5. Awareness and current knowledge of breast cancer;Akram;Biol. Res.,2017
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31
2. CRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-22
3. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials;Journal of Controlled Release;2024-06
4. Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine corpus endometrial carcinoma;Cellular Signalling;2024-05
5. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer;Mini-Reviews in Medicinal Chemistry;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3